$ATXI
Avenue Therapeutics Inc Stock $atxi

$atxi Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000143774924025880 Filed on August 09, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$1.462M
YoY Change		63.17%
% of Gross Profit
Research & Development		$1.361M
YoY Change		-55.04%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$1.361M
YoY Change		-55.04%
Operating Profit		-$2.823M
YoY Change		-28.04%
Interest Expense		$52.00K
YoY Change		-8.77%
% of Operating Profit
Other Income/Expense, Net		$122.0K
YoY Change		-231.18%
Pretax Income		-$2.701M
YoY Change		-32.74%
Income Tax
% Of Pretax Income
Net Earnings		-$2.692M
YoY Change		-32.97%
Net Earnings / Revenue
Basic Earnings Per Share		-$6.43
Diluted Earnings Per Share		-$2.41
COMMON SHARES
Basic Shares Outstanding	1.431M	941.0K
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$4.919M
YoY Change		213.11%
Cash & Equivalents		$4.919M
Short-Term Investments
Other Short-Term Assets		$69.00K
YoY Change		0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$4.988M
YoY Change		199.4%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets		$4.988M
Total Long-Term Assets		$0.00
Total Assets		$4.988M
YoY Change		199.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$592.0K
YoY Change		32.74%
Accrued Expenses		$522.0K
YoY Change		-65.06%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$1.161M
YoY Change		-85.14%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$1.161M
Total Long-Term Liabilities		$0.00
Total Liabilities		$1.161M
YoY Change		-85.14%
SHAREHOLDERS EQUITY
Retained Earnings		-$98.00M
YoY Change		6.41%
Common Stock		$0.00
YoY Change		-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$4.764M
YoY Change
Total Liabilities & Shareholders Equity		$4.988M
YoY Change		199.4%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income		-$2.692M
YoY Change		-32.97%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$2.253M
YoY Change		-51.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.978M
YoY Change
NET CHANGE
Cash From Operating Activities		-2.253M
Cash From Investing Activities		0.000
Cash From Financing Activities		3.978M
Net Change In Cash		1.725M
YoY Change		-125.88%
FREE CASH FLOW
Cash From Operating Activities		-$2.253M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	AVENUE THERAPEUTICS, INC.
	dei	Entity File Number EntityFileNumber	001-38114
	dei	Local Phone Number LocalPhoneNumber	652‑4500
	dei	Entity Central Index Key EntityCentralIndexKey	0001644963
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	250000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	250000
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	250000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	250000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1189724
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1189724
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	341324
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	341324
	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	75	pure
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4113275
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Kane Concourse, Suite 301
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bay Harbor Islands
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33154
	dei	City Area Code CityAreaCode	781
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	ATXI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1431356
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4919000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1783000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	69000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	67000	usd
CY2024Q2	us-gaap	Assets Assets	4988000	usd
CY2023Q4	us-gaap	Assets Assets	1850000	usd
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	47000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	586000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1161000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1196000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	1161000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1196000	usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102724000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	92507000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97960000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90928000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	4764000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1582000	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	-937000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-928000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3827000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	654000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4988000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1850000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1361000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3027000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3752000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4242000	usd
CY2024Q2	atxi	Research And Development Expense For Licenses Acquired ResearchAndDevelopmentExpenseForLicensesAcquired	0	usd
CY2023Q2	atxi	Research And Development Expense For Licenses Acquired ResearchAndDevelopmentExpenseForLicensesAcquired	0	usd
	atxi	Research And Development Expense For Licenses Acquired ResearchAndDevelopmentExpenseForLicensesAcquired	0	usd
	atxi	Research And Development Expense For Licenses Acquired ResearchAndDevelopmentExpenseForLicensesAcquired	4230000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1462000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	896000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2778000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1880000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2823000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3923000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6530000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10352000	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	52000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	57000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	100000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	94000	usd
CY2024Q2	atxi	Financing Costs Warrant Liabilities FinancingCostsWarrantLiabilities	-0	usd
CY2023Q2	atxi	Financing Costs Warrant Liabilities FinancingCostsWarrantLiabilities	-0	usd
	atxi	Financing Costs Warrant Liabilities FinancingCostsWarrantLiabilities	-0	usd
	atxi	Financing Costs Warrant Liabilities FinancingCostsWarrantLiabilities	332000	usd
CY2024Q2	atxi	Loss On Warrant Liabilities Classified As Inducement Fee LossOnWarrantLiabilitiesClassifiedAsInducementFee	185000	usd
CY2023Q2	atxi	Loss On Warrant Liabilities Classified As Inducement Fee LossOnWarrantLiabilitiesClassifiedAsInducementFee	-0	usd
	atxi	Loss On Warrant Liabilities Classified As Inducement Fee LossOnWarrantLiabilitiesClassifiedAsInducementFee	759000	usd
	atxi	Loss On Warrant Liabilities Classified As Inducement Fee LossOnWarrantLiabilitiesClassifiedAsInducementFee	-0	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-255000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	150000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-139000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1028000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	122000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-93000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-520000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1266000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-2701000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-4016000	usd
	us-gaap	Profit Loss ProfitLoss	-7050000	usd
	us-gaap	Profit Loss ProfitLoss	-11618000	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-18000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-75000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2692000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4007000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7032000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11543000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7186000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4007000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15842000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11543000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.43
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-38.74
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-18.86
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-129.84
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1117769
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103442
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	839900
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88901
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1898000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	192000	usd
CY2024Q2	atxi	Common Shares Issuable Founders Agreement CommonSharesIssuableFoundersAgreement	-8000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	172000	usd
CY2024Q2	atxi	Adjustments To Apic Loss On Settlement Of Common Stock Warrant Liabilities AdjustmentsToApicLossOnSettlementOfCommonStockWarrantLiabilities	296000	usd
CY2024Q2	atxi	Stock Issued During Period Value Exercise0f Warrants StockIssuedDuringPeriodValueExercise0fWarrants	4448000	usd
CY2024Q2	atxi	Adjustments To Additional Paid In Capital Warrant Inducement Offering Costs AdjustmentsToAdditionalPaidInCapitalWarrantInducementOfferingCosts	765000	usd
CY2024Q2	atxi	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
CY2024Q2	atxi	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2692000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3827000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	654000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	383000	usd
	atxi	Common Shares Issuable Founders Agreement CommonSharesIssuableFoundersAgreement	-371000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	543000	usd
	atxi	Adjustments To Apic Loss On Settlement Of Common Stock Warrant Liabilities AdjustmentsToApicLossOnSettlementOfCommonStockWarrantLiabilities	1159000	usd
	atxi	Stock Issued During Period Value Exercise0f Warrants StockIssuedDuringPeriodValueExercise0fWarrants	9421000	usd
	atxi	Adjustments To Additional Paid In Capital Warrant Inducement Offering Costs AdjustmentsToAdditionalPaidInCapitalWarrantInducementOfferingCosts	-1207000	usd
	atxi	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
	atxi	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-18000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7032000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3827000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2157000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27000	usd
CY2023Q2	atxi	Stock Issued During Period Value Exercise0f Warrants StockIssuedDuringPeriodValueExercise0fWarrants	0	usd
CY2023Q2	atxi	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4007000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6146000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3266000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	72000	usd
	atxi	Shares And Warrants Issued During Period Value SharesAndWarrantsIssuedDuringPeriodValue	866000	usd
	atxi	Stock Issued During Period Value License Expense StockIssuedDuringPeriodValueLicenseExpense	1230000	usd
	atxi	Stock Issued During Period Value Exercise0f Warrants StockIssuedDuringPeriodValueExercise0fWarrants	0	usd
	atxi	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-75000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11543000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6146000	usd
	us-gaap	Profit Loss ProfitLoss	-7050000	usd
	us-gaap	Profit Loss ProfitLoss	-11618000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	383000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	38000	usd
	atxi	Loss On Warrant Liabilities Classified As Inducement Fee LossOnWarrantLiabilitiesClassifiedAsInducementFee	759000	usd
	atxi	Loss On Warrant Liabilities Classified As Inducement Fee LossOnWarrantLiabilitiesClassifiedAsInducementFee	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-139000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1028000	usd
	atxi	Issuance Of Stock For Licenses Acquired IssuanceOfStockForLicensesAcquired	0	usd
	atxi	Issuance Of Stock For Licenses Acquired IssuanceOfStockForLicensesAcquired	1230000	usd
	atxi	Research And Development License Acquried Expense ResearchAndDevelopmentLicenseAcquriedExpense	0	usd
	atxi	Research And Development License Acquried Expense ResearchAndDevelopmentLicenseAcquriedExpense	2000000	usd
	atxi	Common Stock Issued To Fortress Value CommonStockIssuedToFortressValue	543000	usd
	atxi	Common Stock Issued To Fortress Value CommonStockIssuedToFortressValue	72000	usd
	atxi	Issuance Of Stock Under Founders Agreement IssuanceOfStockUnderFoundersAgreement	-371000	usd
	atxi	Issuance Of Stock Under Founders Agreement IssuanceOfStockUnderFoundersAgreement	0	usd
	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-0	usd
	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	26000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-68000	usd
	atxi	Increase Decrease In Accrued Licenses Acquired IncreaseDecreaseInAccruedLicensesAcquired	0	usd
	atxi	Increase Decrease In Accrued Licenses Acquired IncreaseDecreaseInAccruedLicensesAcquired	1000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5373000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6238000	usd
	atxi	Payments To Acquire Research And Development Licenses PaymentsToAcquireResearchAndDevelopmentLicenses	-0	usd
	atxi	Payments To Acquire Research And Development Licenses PaymentsToAcquireResearchAndDevelopmentLicenses	2000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000000	usd
	atxi	Issuance Of Common Stock Prefund Warrants And Warrants IssuanceOfCommonStockPrefundWarrantsAndWarrants	0	usd
	atxi	Issuance Of Common Stock Prefund Warrants And Warrants IssuanceOfCommonStockPrefundWarrantsAndWarrants	3101000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	295000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9421000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	atxi	Payments Of Warrants Exercise Transaction Costs PaymentsOfWarrantsExerciseTransactionCosts	1207000	usd
	atxi	Payments Of Warrants Exercise Transaction Costs PaymentsOfWarrantsExerciseTransactionCosts	-0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8509000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3101000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3136000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5137000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1783000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6708000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4919000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1571000	usd
	atxi	Unpaid Research And Development Licenses Acquired UnpaidResearchAndDevelopmentLicensesAcquired	0	usd
	atxi	Unpaid Research And Development Licenses Acquired UnpaidResearchAndDevelopmentLicensesAcquired	1000000	usd
	us-gaap	Stock Issued1 StockIssued1	543000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98000000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q2	atxi	Deemed Dividends DeemedDividends	4500000	usd
	atxi	Deemed Dividends DeemedDividends	8800000	usd
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1499925
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	105051
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	286912
CY2019Q4	atxi	Contractual Obligation Development Expense ContractualObligationDevelopmentExpense	81500000	usd
CY2019Q4	atxi	Contractual Obligation Commercial Expense ContractualObligationCommercialExpense	151000000	usd
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1311000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	196.21
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	-0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	283000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	85.5
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1028000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	226.69
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1028000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	226.69
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22474000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	85.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22474000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	85.5
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	16304000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	85.5
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6170000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	85.5
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	192000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	383000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	524601
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	32.42
CY2023	atxi	Class Of Warrant Or Right Aggregate Intrinsic Value ClassOfWarrantOrRightAggregateIntrinsicValue	0	usd
CY2024Q1	atxi	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	441076
CY2024Q1	atxi	Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights	6.2
CY2024Q1	atxi	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	220538
CY2024Q1	atxi	Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights	22.55
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	745139
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	29.5
CY2024Q1	atxi	Class Of Warrant Or Right Aggregate Intrinsic Value ClassOfWarrantOrRightAggregateIntrinsicValue	0	usd
CY2024Q2	atxi	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	1420741
CY2024Q2	atxi	Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights	6.25
CY2024Q2	atxi	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	689680
CY2024Q2	atxi	Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights	6.2
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1476200
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.64
CY2024Q2	atxi	Class Of Warrant Or Right Aggregate Intrinsic Value ClassOfWarrantOrRightAggregateIntrinsicValue	0	usd

Files In Submission

Name	View Source	Status
0001437749-24-025880-index-headers.html	Edgar Link	pending
0001437749-24-025880-index.html	Edgar Link	pending
0001437749-24-025880.txt	Edgar Link	pending
0001437749-24-025880-xbrl.zip	Edgar Link	pending
atxi-20240630.xsd	Edgar Link	pending
atxi20240630_10q.htm	Edgar Link	pending
ex_677266.htm	Edgar Link	pending
ex_677267.htm	Edgar Link	pending
ex_677268.htm	Edgar Link	pending
ex_677269.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
atxi-20240630_def.xml	Edgar Link	unprocessable
atxi-20240630_lab.xml	Edgar Link	unprocessable
atxi-20240630_pre.xml	Edgar Link	unprocessable
atxi20240630_10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
atxi-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATXI
Avenue Therapeutics Inc Stock $atxi

2024 Q3 Form 10-Q Financial Statement

#000143774924025880 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXI Avenue Therapeutics Inc Stock $atxi

2024 Q3 Form 10-Q Financial Statement

#000143774924025880 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXI
Avenue Therapeutics Inc Stock $atxi